Moderna nearing deal with US government to develop Ebola vaccines — report
The biggest pandemic biotech darling is reportedly one step closer to securing a new deal for other serious infectious diseases.
Moderna is nearing an agreement with the US government to develop vaccines for Ebola and additional viruses considered to be threats, Bloomberg reported Wednesday. The deal is expected to see Moderna work with researchers from the University of Texas Medical Branch at Galveston to emulate its rapid approach to Covid-19 for such viruses.
Bloomberg noted the deal has not yet been finalized and financial terms were not available. Endpoints News has reached out to Moderna for comment and will update this story accordingly.
The current plan is to develop an Ebola vaccine targeting the strain involved in the Uganda outbreak, Bloomberg reported, where 95 people have been infected. Discussions began before the virus started spreading there, however.
Moderna’s Ebola efforts appear to be new as well, as the company does not mention the virus on its website or in previous press releases. Most of its mRNA research has gone towards Covid-19, but it’s also working on vaccines for flu, HIV, RSV, cancer, Epstein-Barr virus, the common cold and more.
For BARDA, the priority remains to secure vaccines and treatments to prepare the US for future pandemics. The department has invested about $165 million in Ebola vaccines so far, a spokesperson told Bloomberg, and BARDA has taken other initiatives to prep for outbreaks, such as handing out a $62 million contract to Arcturus to develop an mRNA flu shot.